A HPLC-Q-TOF-MS-based urinary metabolomic approach to identification of potential biomarkers of metabolic syndrome

Journal of Huazhong University of Science and Technology - Medical Science

Volumn 34, Issue 2, 2014, Pages 276-283

  Yu, Zhi Rui ^a,b   Ning, Yu ^a,c   Yu, Hao ^a   Tang, Nai Jun ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b Tianjin Entry Exit Inspection Quarantine Bureau   (China)

^c CNOOC Center for Disease Control and Prevention   (China)

Author keywords

biomarker; HPLC Q TOF MS; metabolic syndrome; metabolomics; urine

Indexed keywords

BIOLOGICAL MARKER;

ADULT; ARTICLE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MASS SPECTROMETRY; METABOLIC SYNDROME X; METABOLOMICS; MIDDLE AGED; PRINCIPAL COMPONENT ANALYSIS; URINE;

ADULT; BIOLOGICAL MARKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; METABOLIC SYNDROME X; METABOLOMICS; MIDDLE AGED; PRINCIPAL COMPONENT ANALYSIS;

EID: 84898858961     PISSN: 16720733     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11596-014-1271-7     Document Type: Article

References (38)

1. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome - a new worldwide definition. Lancet, 2005, 366(9491):1059-1062
2. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation, 2009,120(16):1640-1645
3. Gu D, Reynolds K, Wu X, et al. Prevalence of the metabolic syndrome and overweight among adults in China. Lancet, 2005,365(9468):1398-1405
4. Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol, 2007,49(4):403-414
5. Kahn R, Buse J, Ferrannini E, et al. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2005,28(9):2289-2304
6. Eckel RH, Alberti KG, Grundy SM, et al. The metabolic syndrome. Lancet, 2010,375(9710):181-183
7. Kadowaki T, Yamauchi T, Kubota N, et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest, 2006,116(7): 1784-1792
8. Esteghamati A, Zandieh A, Zandieh B, et al. Leptin cut-off values for determination of metabolic syndrome: third national surveillance of risk factors of non-communicable diseases in Iran (SuRFNCD-2007). Endocrine, 2011,40(1):117-123
9. Timpson NJ, Lawlor DA, Harbord RM, et al. C-reactive protein and its role in metabolic syndrome: mendelian randomisation study. Lancet, 2005,366(9501):1954-1959
10. Nicholson JK, Wilson ID. Opinion: understanding 'global' systems biology: metabonomics and the continuum of metabolism. Nat Rev Drug Discov, 2003,2(8): 668-676
11. Raamsdonk LM, Teusink B, Broadhurst D, et al. A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations. Nat Biotechnol, 2001,19(1):45-50
12. An J, Muoio DM, Shiota M, et al. Hepatic expression of malonyl-CoA decarboxylase reverses muscle, liver and whole-animal insulin resistance. Nat Med, 2004,10(3): 268-274
13. Ong ES, Zou L, Li S, et al. Metabolic profiling in colorectal cancer reveals signature metabolic shifts during tumorigenesis. Mol Cell Proteomics, 2010 [PMID: 20147338]
14. Wang TJ, Larson MG, Vasan RS, et al. Metabolite profiles and the risk of developing diabetes. Nat Med, 2011,17(4):448-453
15. Lv H, Hung CS, Chaturvedi KS, et al. Development of an integrated metabolomic profiling approach for infectious diseases research. Analyst, 2011,136(22):4752-4763
16. Othman A, Rutti MF, Ernst D, et al. Plasma deoxysphingolipids: a novel class of biomarkers for the metabolic syndrome? Diabetologia, 2012,55(2):421-431
17. Zhang T, Wu X, Ke C, et al. Identification of potential biomarkers for ovarian cancer by urinary metabolomic profiling. J Proteome Res, 2013,12(1):505-512
18. Dunn WB, Wilson ID, Nicholls AW, et al. The importance of experimental design and QC samples in large-scale and MS-driven untargeted metabolomic studies of humans. Bioanalysis, 2012,4(18):2249-2264
19. Bijlsma S, Bobeldijk I, Verheij ER, et al. Large-scale human metabolomics studies: a strategy for data (pre-) processing and validation. Anal Chem, 2006,78(2): 567-574
20. An Z, Chen Y, Zhang R, et al. Integrated ionization approach for RRLC-MS/MS-based metabonomics: finding potential biomarkers for lung cancer. J Proteome Res, 2010,9(8):4071-4081
21. Zhu Z, Wang H, Shang Q, et al. Time course analysis of candida albicans metabolites during biofilm development. J Proteome Res, 2013,12(6):2375-2385
22. Zhang F, Jia Z, Gao P, et al. Metabonomics study of atherosclerosis rats by ultra fast liquid chromatography coupled with ion trap-time of flight mass spectrometry. Talanta, 2009,79(3):836-844
23. Wurtz P, Tiainen M, Makinen VP, et al. Circulating metabolite predictors of glycemia in middle-aged men and women. Diabetes Care, 2012,35(8):1749-1756
24. Wurtz P, Soininen P, Kangas AJ, et al. Branched-chain and aromatic amino acids are predictors of insulin resistance in young adults. Diabetes Care, 2013,36(3):648-655
25. Patti M E, Brambilla E, Luzi L, et al. Bidirectional modulation of insulin action by amino acids. J Clin Invest, 1998,101(7):1519-1529
26. Newgard CB, An J, Bain JR, et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab, 2009,9(4):311-326
27. Soares-da-Silva P, Vieira-Coelho MA, Pinto-do OP, et al. Studies on the nature of the antagonistic actions of dopamine and 5-hydroxytryptamine in renal tissues. Hypertens Res, 1995, 18(Suppl 1):S47-S51
28. Hirose M, Tomoda F, Koike T, et al. Imbalance of renal production between 5-hydroxytryptamine and dopamine in patients with essential hypertension complicated by microalbuminuria. Am J Hypertens, 2013,26(2):227-233
29. Adams S H. Emerging perspectives on essential amino acid metabolism in obesity and the insulin-resistant state. Adv Nutr, 2011,2(6):445-456
30. Mihalik SJ, Goodpaster BH, Kelley DE, et al. Increased levels of plasma acylcarnitines in obesity and type 2 diabetes and identification of a marker of glucolipotoxicity. Obesity (Silver Spring), 2010,18(9):1695-1700
31. Schooneman MG, Vaz FM, Houten SM, et al. Acylcarnitines: reflecting or inflicting insulin resistance? Diabetes, 2013,62(1):1-8
32. Sharma S, Sud N, Wiseman DA, et al. Altered carnitine homeostasis is associated with decreased mitochondrial function and altered nitric oxide signaling in lambs with pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol, 2008, 294(1):L46-56
33. Satapati S, Sunny N E, Kucejova B, et al. Elevated TCA cycle function in the pathology of diet-induced hepatic insulin resistance and fatty liver. J Lipid Res, 2012, 53(6):1080-1092
34. Cusi K. Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis. Clin Liver Dis, 2009,13(4): 545-563
35. Catania VA, Carrillo MC. Intestinal phase II detoxification systems: effect of low-protein diet in weanling rats. Toxicol Lett, 1990,54(2-3):263-270
36. Xu J, Kulkarni SR, Li L, et al. UDP-glucuronosyltransferase expression in mouse liver is increased in obesity- and fasting-induced steatosis. Drug Metab Dispos, 2012,40(2):259-266
37. Guan HP, Goldstein JL, Brown MS, et al. Accelerated fatty acid oxidation in muscle averts fasting-induced hepatic steatosis in SJL/J mice. J Biol Chem, 2009,284(36): 24644-24652
38. Osabe M, Sugatani J, Fukuyama T, et al. Expression of hepatic UDP-glucuronosyltransferase 1A1 and 1A6 correlated with increased expression of the nuclear constitutive androstane receptor and peroxisome proliferator- activated receptor alpha in male rats fed a high-fat and high-sucrose diet. Drug Metab Dispos, 2008,36(2): 294-302